Analysts cheer ‘surprisingly positive’ AstraZeneca U.S. trial data

Jefferies healthcare analyst Peter Welford said the analysis of the AstraZeneca shot, published Monday, was better than expected.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.